ライフサイエンスコーパス: stable angina

1 tion (60.8% patients with ACS and 39.2% with stable angina).

2 DES for AMI and compared with patients with stable angina.

3 dical therapy is a proven option for chronic stable angina.

4 ith an acute myocardial infarction than with stable angina.

5 ations and evidence-based medical therapy in stable angina.

6 in 14 patients with ACS and 9 patients with stable angina.

7 nd in stable lesions in patients with ACS or stable angina.

8 ith an acute myocardial infarction than with stable angina.

9 lable rho kinase inhibitor, in patients with stable angina.

10 s on the management of patients with chronic stable angina.

11 e on the management of patients with chronic stable angina.

12 e on the management of patients with chronic stable angina.

13 c plaque complexity in patients with chronic stable angina.

14 in patients with a new diagnosis of chronic stable angina.

15 er design, we enrolled 336 CAD patients with stable angina.

16 aspects of quality of life in patients with stable angina.

17 m-derived nitric oxide (NO) in patients with stable angina.

18 oncentrations than did patients with chronic stable angina.

19 rate (ISMN) or glyceryl trinitrate (GTN) for stable angina.

20 ts in randomized trials of patients who have stable angina.

21 y aspirin treatment in patients with chronic stable angina.

22 anatomic extent of disease in patients with stable angina.

23 new clinical domains beyond the confines of stable angina.

24 d toward an ad hoc approach in patients with stable angina.

25 7 for management of hypertension and chronic stable angina.

26 coronary arterial stenoses in patients with stable angina.

27 ary artery stenoses in patients with chronic stable angina.

28 , respectively, p = 0.03) than patients with stable angina.

29 bout its importance in patients with chronic stable angina.

30 th intravascular ultrasound in patients with stable angina.

31 ain across a broad spectrum of patients with stable angina.

32 ith best medical therapy among patients with stable angina.

33 of ranolazine in patients with diabetes and stable angina.

34 f patients in both cohorts underwent PCI for stable angina.

35 sites in patients with ACS versus those with stable angina.

36 ther non-ST segment elevation MI (NSTEMI) or stable angina.

37 nts; and 15 (3.0%) patients hospitalized for stable angina.

38 mmon in patients with ACS than in those with stable angina.

39 se microvascular resistance in patients with stable angina.

40 cardial infarctions compared with those with stable angina.

41 exercise capability in patients with chronic stable angina.

42 rachnoid haemorrhage (1.43 [1.25-1.63]), and stable angina (1.41 [1.36-1.46]), and weakest for abdomi

43 3.22]), ischaemic stroke (1.72 [1.52-1.95]), stable angina (1.62 [1.49-1.77]), heart failure (1.56 [1

44 6-3.22), ischaemic stroke (1.72, 1.52-1.95), stable angina (1.62, 1.49-1.77), heart failure (1.56, 1.

45 or myocardial infarction (MI, 33%), but also stable angina (11%) or no symptoms (11%).

46 % CI: 0.53 to 2.10; p = 0.88) and those with stable angina (11.6% vs. 15.8%; HR: 0.82; 95% CI: 0.50 t

47 arger in unstable angina (42 +/- 3%) than in stable angina (18 +/- 4%) (P = .0001).

48 cost differences of $1,300 for patients with stable angina, $2,100 for patients with unstable angina

49 percent had unstable angina), 6 percent had stable angina, 21 percent had other cardiac problems, an

50 patients compared with those who had chronic stable angina (28.4 versus 14.0 pg/mL; 95% CI, 9.8 to 19

51 (n = 401) or DES (n = 399) for treatment of stable angina (32%) or acute coronary syndrome (68%).

52 7 +/- 8%) than in samples from patients with stable angina (40 +/- 5%) (P = .00007).

53 arger in unstable angina (16 +/- 2%) than in stable angina (5 +/- 2%) (P = .002).

54 eous coronary intervention were included: 50 stable angina, 50 NSTEMI, and 40 STEMI.

55 The remaining 83 were being evaluated for stable angina (53), valvular heart disease (8), atypical

56 ) prospectively randomized 350 patients with stable angina (55% women; aged 55+/-10 years), mostly wi

57 (CD66b) was similar in patients with ACS and stable angina (6.61 [4.91-7.72] versus 6.62 [5.27-8.73],

58 ts with ACS and less common in patients with stable angina (73.3% versus 17.6%, P=0.002).

59 rwent percutaneous coronary intervention for stable angina (77.9% versus 46.2%).

60 omposed of LCP than targets in patients with stable angina (84.4% versus 52.8%, P=0.004), approximate

61 undergoing cardiac catheterization (65 with stable angina, 84 with unstable angina or a myocardial i

62 ndex age 30 years, whereas heart failure and stable angina accounted for the largest proportion (19%

63 The coronary arteries of patients with stable angina also contain many nonobstructive plaques,

64 ripheral blood T cells from 34 patients with stable angina and 34 patients with UA were compared for

65 were compared with those of 40 patients with stable angina and 40 healthy controls.

66 nts undergoing coronary angiography, 37 with stable angina and 50 with unstable angina or a myocardia

67 Within stable angina and ACS cohorts, 7% of patients were black

68 ol/10(8) platelets in coronary patients with stable angina and acute coronary syndromes, respectively

69 Fifteen patients with chronic stable angina and angiographically proven CAD (>70% sten

70 ronary revascularization among patients with stable angina and at least 1 coronary lesion with a frac

71 uation) trial enrolled patients with chronic stable angina and at least 1 significant (> or =70%) ang

72 adverse prognosis observed among women with stable angina and confirmed coronary disease.

73 myocardial infarction than in patients with stable angina and controls (P<0.001).

74 mmarizes the current evidence for its use in stable angina and heart failure and its future direction

75 epression is common in patients with chronic stable angina and is associated with increased morbidity

76 percutaneous coronary intervention (PCI) in stable angina and is commonly observed clinically.

77 Twenty-eight patients with stable angina and ischemia documented by a stress test w

78 ion, and more chronic disease states such as stable angina and ischemic cardiomyopathy.

79 g hemorrhagic complications in patients with stable angina and non-ST-segment elevation acute coronar

80 Twenty-four men with chronic stable angina and normal left ventricular function under

81 nary intervention (PCI) reduces only chronic stable angina and not myocardial infarction (MI) or asso

82 The resistive reserve ratio was similar in stable angina and NSTEMI patients (P=0.6).

83 Fifty-two patients with stable angina and reversible ischemia comprising >9% of

84 n all patient subgroups those with including stable angina and single-vessel disease.

85 e investigation and subsequent management of stable angina and to assess gender differences in clinic

86 non-ST-elevation acute coronary syndromes or stable angina and to evaluate long-term outcomes of none

87 unstable angina compared with patients with stable angina and to investigate the effect of percutane

88 infarction, 20 with unstable angina, 19 with stable angina, and 13 controls without atherosclerosis.

89 theterization with asymptomatic/mild angina, stable angina, and unstable angina/non-ST-elevation myoc

90 dual aims of treating patients with chronic stable angina are 1) to reduce morbidity and mortality a

91 of lipid core plaque (LCP), lesions causing stable angina are believed to be composed of fibrocalcif

92 rs after PCI, and type IVa MI was defined in stable angina as a rise of at least 3x upper reference l

93 ting with acute myocardial infarction versus stable angina as the initial manifestation of CHD.

94 ts before and after coronary angioplasty for stable angina at three sampling sites: the femoral arter

95 t included patients in Ontario, Canada, with stable angina based on obstructive coronary artery disea

96 Among patients with stable angina, both those treated with PCI and those tre

97 antianginal agent that has been effective in stable angina, but it has not been studied in the settin

98 duction should benefit patients with chronic stable angina by improving myocardial perfusion and redu

99 Patients with suspected chronic stable angina can be evaluated in three stages.

100 Seventy-nine patients with chronic stable angina Canadian Cardiovascular Society class 2 or

101 the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial from July 1999 to August 20

102 Women have a similarly high incidence of stable angina compared with men.

103 Forty-six men with stable angina completed a 2-week, single-blind placebo r

104 lesions in ACS and stable lesions in ACS or stable angina, consistent with previous intravascular ul

105 one half of target lesions in patients with stable angina contained LCP.

106 me (ACS) compared with patients with chronic stable angina (CSA).

107 usion percutaneous coronary intervention for stable angina (CTO-PCI) is a rare but serious event.

108 ial clinical experience in six patients with stable angina demonstrates that high-quality NIR spectra

109 men, mean age 60.1+/-2.3 years) with chronic stable angina due to angiographically documented coronar

110 e culprit site in patients receiving DES for stable angina, emphasizing the importance of underlying

111 Randomized trials in patients with chronic stable angina enroll few patients who are over age 65 ye

112 The Euro Heart Survey of Stable Angina enrolled patients with a clinical diagnosi

113 ion to current traditional drugs for chronic stable angina, especially in aggressive multidrug regime

114 betes mellitus, coronary artery disease, and stable angina from the multinational Type 2 Diabetes Eva

115 ing diagnostic angiography for assessment of stable angina had angiographically normal or near normal

116 18 (45%) patients with stable angina had plaques with focal (18)F-NaF uptake (m

117 alternative therapies for many patients with stable angina; however, patients may have misconceptions

118 Clinical indications included stable angina in 22.5% of cases, unstable angina in 31.9

119 angina was present in 95 patients (78%) and stable angina in 27 (22%).

120 lacebo were administered to 15 subjects with stable angina in a double-blind crossover trial.

121 Furthermore, stable angina in women is associated with increased coro

122 Among patients with stable angina, in hospitals with high-capacity CCUs, use

123 ography for acute coronary syndrome (ACS) or stable angina, in whom there is angiographic evidence fo

124 most effective as a first-line treatment for stable angina is not known.

125 , through modest (hazard ratio, 1.5-2.0) for stable angina, ischemic stroke, peripheral arterial dise

126 n in Patients With Normal Blood Pressure and Stable Angina?; ISRCTN73579730).

127 the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-r

128 ents with UA and infrequent in patients with stable angina (median frequencies: 10.8% versus 1.5%, P<

129 tients with myocardial infarction (n = 7) or stable angina (n = 10) underwent (18)F-NaF PET and prosp

130 ients with ACS (n = 13) and in patients with stable angina (n = 13) (17.5 +/- 5.9 mm2 vs. 9.1 +/- 4.8

131 ents referred for angiographic evaluation of stable angina (n=375,886) or acute coronary syndromes (A

132 tients with myocardial infarction (n=40) and stable angina (n=40) underwent (18)F-NaF and (18)F-FDG P

133 he US and approximately 400,000 new cases of stable angina occur each year.

134 rolled patients with a clinical diagnosis of stable angina on initial assessment by a cardiologist.

135 among patients who underwent PCI for either stable angina or a positive stress test.

136 of patients developing stroke after PCI for stable angina or acute coronary syndrome (ACS) in daily

137 ase activity increases in men and women with stable angina or acute coronary syndromes, supporting pr

138 A total of 2037 participants with stable angina or an acute coronary syndrome who had an i

139 Among patients with stable angina or an acute coronary syndrome, an iFR-guid

140 % CI: 1.17 to 1.57), but no association with stable angina or intracerebral hemorrhage.

141 vention (PCI), particularly in patients with stable angina or ischemia, in whom event rates are low i

142 entified: elevated troponin (OR, 3.9), prior stable angina (OR, 1.8), ST-segment deviation >or=0.5 mm

143 ngs where the intrinsic risks are low (e.g., stable angina) or in which the device used carries a red

144 1.2% in unstable rest angina versus 18.3% in stable angina (p = 0.05); alpha-actin area was greater i

145 compared with 4 of 25 arteries in those with stable angina (p less than 0.0001) in whom an "angina-pr

146 seen more frequently in the 47 patients with stable angina (p less than 0.05).

147 was reported for white women presenting with stable angina (P<0.00001).

148 odds ratio for mortality than white men with stable angina (P<0.0001), with higher rates noted for wh

149 In patients with stable angina, PAPP-A and PAPP-A/proMBP ratio are associ

150 c) were higher in ACS patients compared with stable angina patients (1.38 [1.16-1.52] versus 1.17 [1-

151 We studied 396 stable angina patients (age 63+/-10 years, 230 men) of w

152 mean plaque Lp(a) areas than specimens from stable angina patients (n = 26): 64.4% versus 47.7% (p =

153 plicated in an independent population of 482 stable angina patients (rSA) and of 675 ACS patients, re

154 ectoris had higher VEGF levels compared with stable angina patients and healthy control subjects (P<0

155 ower in the STEMI patients compared with the stable angina patients both culprit and nonculprit vesse

156 mples of 2,000 persons drawn from the 10,128 stable angina patients in the CALIBER database with comp

157 We prospectively enrolled 11,372 consecutive stable angina patients who were referred for stress myoc

158 on-based cohort study on 49 556 adult ACS or stable angina patients with angiographic evidence of obs

159 ute cardiac events in predominantly low-risk stable angina patients with confirmed coronary disease a

160 patients than in a control group of chronic stable angina patients with multivessel IVUS imaging.

161 cacy and safety of fasudil were evaluated in stable angina patients.

162 This was not observed in stable angina patients.

163 28(null) T cells from circulation of ACS and stable angina patients.

164 cardial infarction (n=5371, 901 deaths), and stable angina pectoris (n=6536, 965 deaths) in 4 age cat

165 elective coronary angiography for suspected stable angina pectoris (SAP) (n = 4131) and an independe

166 203 patients referred for angiography due to stable angina pectoris (SAP) or acute coronary syndrome

167 egment elevation AMI and unstable angina, or stable angina pectoris (SAP).

168 -segment-elevation myocardial infarction and stable angina pectoris , similar patterns were found alb

169 Male patients (n = 328) with stable angina pectoris and ischemia on treadmill testing

170 tations is coronary heart disease, including stable angina pectoris and the acute coronary syndromes.

171 erformance than medical therapy for men with stable angina pectoris due to single-vessel disease.

172 The indication for PTCA was stable angina pectoris in 69 patients, unstable angina i

173 Stable angina pectoris in women has often been considere

174 Rapid CAD progression in patients with stable angina pectoris is associated with increased C-re

175 We studied 124 chronic stable angina pectoris patients (84 men; mean age, 61+/-

176 analysis at rest in patients with suspected stable angina pectoris predicts the presence of coronary

177 emia during patch-off hours in patients with stable angina pectoris receiving a beta-adrenergic block

178 Patients (n=141) with stable angina pectoris undergoing PCI had serial venous

179 n Trial) undergoing coronary angiography for stable angina pectoris were studied.

180 sion of ambulatory ischemia in patients with stable angina pectoris, but it remains to be established

181 In patients with suspected stable angina pectoris, global longitudinal peak systoli

182 nsecutive patients with clinically suspected stable angina pectoris, no previous cardiac history, and

183 e of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Assoc

184 Eligible patients had stable angina pectoris, unstable angina pectoris, or non

185 -culprit plaques in patients presenting with stable angina pectoris, unstable angina pectoris,and ST-

186 s of sGPVI were observed in 10 patients with stable angina pectoris, with well-defined single vessel

187 s been approved for the treatment of chronic stable angina pectoris.

188 infarction, in chronic heart failure, and in stable angina pectoris.

189 sent with either acute coronary syndromes or stable angina pectoris.

190 pid CAD progression in patients with chronic stable angina pectoris.

191 dipine on long-term outcome in patients with stable angina pectoris.

192 differed between patients with unstable and stable angina pectoris.

193 ia and angina pectoris in most patients with stable angina pectoris.

194 in patients with ischemic heart disease and stable angina pectoris.

195 rs) effect adverse outcomes in patients with stable angina pectoris.

196 erance, symptoms and myocardial perfusion in stable angina pectoris.

197 e, prior myocardial infarction, unstable and stable angina, recent coronary artery bypass graft, and

198 l testosterone treatment in men with chronic stable angina reduces exercise-induced myocardial ischem

199 oaches to diagnose ischemia in patients with stable angina referred for invasive coronary angiography

200 diagnosis of acute infarction (Al) (n = 20), stable angina (SA) (n = 20), and unstable angina (UA) (n

201 gamma driven, patients with unstable (UA) or stable angina (SA) were compared for nuclear translocati

202 tion myocardial infarction (NSTEMI), 20 with stable angina (SA), and 20 controls.

203 going percutaneous coronary intervention for stable angina (SA), unstable angina (UA), or acute myoca

204 ts with UA (Braunwald's class IIIB) and with stable angina (SA).

205 with a model of preserved microcirculation (stable angina [SA] cohort: culprit and nonculprit vessel

206 coronary angiography for suspected CAD (432 stable angina [SA], 572 acute coronary syndrome [ACS]) w

207 For patients with chronic stable angina, several randomized trials have been perfo

208 HODS AND Patients referred for evaluation of stable angina symptoms underwent adenosine-stress dynami

209 ation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) trial.

210 ation of Ranolazine in Subjects With Chronic Stable Angina [TERISA]; NCT01425359).

211 Ranolazine is an approved drug for chronic stable angina that acts by suppressing a noninactivating

212 s in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly hei

213 In stable angina, the risk-adjusted OR for significant CAD

214 In a multinational cohort of patients with stable angina, the SAQ angina frequency domain was signi

215 efficacy of bypass surgery in patients with stable angina, there are relatively few studies that hav

216 placebo in patients with diabetes, CAD, and stable angina treated with 1 to 2 antianginals.

217 procedural outcome measures in patients with stable angina undergoing percutaneous coronary intervent

218 tients with acute coronary syndrome (ACS) or stable angina underwent coronary 16-slice MDCT and invas

219 we included 1,379 consecutive patients with stable angina, unobstructed coronaries and ACH test perf

220 cal strata based on the indication for PTCA (stable angina, unstable angina and after myocardial infa

221 in all three presenting clinical syndromes (stable angina, unstable angina, and MI).

222 free of CHD at baseline and in patients with stable angina, unstable angina, or a history of myocardi

223 However, their role in stable angina versus unstable angina is less well define

224 atients with recent-onset chest pain in whom stable angina was suspected.

225 ation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-

226 ergoing directional coronary atherectomy for stable angina were analyzed for immunoreactivity for ET-

227 e angina and 15 specimens from patients with stable angina were analyzed.

228 Patients with ACS and those with stable angina were compared for the frequency of LCP at

229 S and stable lesions in patients with ACS or stable angina were determined.

230 ents with a > or =3-month history of chronic stable angina were randomly assigned to receive ivabradi

231 Forty patients with stable angina were studied before and following percutan

232 , coronary artery disease (CAD), and chronic stable angina who remain symptomatic despite treatment w

233 Twenty-six patients who had stable angina with thick-cap fibroatheroma treated by DE

234 Of these, 50 patients had chronic stable angina (with stable symptoms over 3 months), and

235 ents with systolic heart failure and chronic stable angina without clinically significant adverse eff